JP2022540000A5 - - Google Patents
Info
- Publication number
- JP2022540000A5 JP2022540000A5 JP2021576778A JP2021576778A JP2022540000A5 JP 2022540000 A5 JP2022540000 A5 JP 2022540000A5 JP 2021576778 A JP2021576778 A JP 2021576778A JP 2021576778 A JP2021576778 A JP 2021576778A JP 2022540000 A5 JP2022540000 A5 JP 2022540000A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962868057P | 2019-06-28 | 2019-06-28 | |
| US62/868,057 | 2019-06-28 | ||
| US202062960817P | 2020-01-14 | 2020-01-14 | |
| US62/960,817 | 2020-01-14 | ||
| US202063031719P | 2020-05-29 | 2020-05-29 | |
| US63/031,719 | 2020-05-29 | ||
| PCT/IB2020/056066 WO2020261205A1 (en) | 2019-06-28 | 2020-06-26 | Thieno[3,2-b]thiophene-2-carboxylic acid compounds having bckdk inhibiting activity |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022540000A JP2022540000A (ja) | 2022-09-14 |
| JP2022540000A5 true JP2022540000A5 (https=) | 2023-06-02 |
| JPWO2020261205A5 JPWO2020261205A5 (https=) | 2023-06-02 |
Family
ID=71452516
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021576778A Pending JP2022540000A (ja) | 2019-06-28 | 2020-06-26 | Ｂｃｋｄｋ阻害活性を有するチエノ［３，２－ｂ］チオフェン－２－カルボン酸化合物 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11542270B2 (https=) |
| EP (1) | EP3990461A1 (https=) |
| JP (1) | JP2022540000A (https=) |
| CA (1) | CA3144869C (https=) |
| PY (1) | PY2030111A (https=) |
| TW (1) | TW202115086A (https=) |
| UY (1) | UY38768A (https=) |
| WO (1) | WO2020261205A1 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202115086A (zh) * | 2019-06-28 | 2021-04-16 | 美商輝瑞大藥廠 | Bckdk抑制劑 |
| TW202228762A (zh) * | 2020-01-30 | 2022-08-01 | 美商美國禮來大藥廠 | 提派肽(tirzepatide)之治療用途 |
| WO2022161915A1 (en) * | 2021-01-27 | 2022-08-04 | Koninklijke Philips N.V. | Apparatus and method for augmented interpretation of magnetic resonance and ultrasound shear wave elastography for monitoring liver fibrosis |
| EP4294812A4 (en) * | 2021-02-21 | 2025-03-26 | Ramino-Bio Ltd. | Thiophene based compounds and use thereof as bckdk inhibitors |
| US12605702B2 (en) | 2021-04-26 | 2026-04-21 | Reprieve Cardiovascular, Inc. | Measuring and/or detecting analytes in urine, and associated systems, devices, and methods |
| JP2024526669A (ja) * | 2021-07-12 | 2024-07-19 | リプリーヴ カーディオヴァスキュラー インコーポレイテッド | 推定過剰流体に基づく流体療法及び関連のシステム及び方法 |
| CR20240183A (es) * | 2021-12-01 | 2024-06-07 | Pfizer | Inhibidores y/o degradadores de bckdk |
| CN114903994A (zh) * | 2022-04-19 | 2022-08-16 | 上海交通大学医学院附属瑞金医院 | Bckdk作为靶点在制备2型糖尿病药物中的应用 |
| EP4695226A1 (en) | 2023-04-14 | 2026-02-18 | Pfizer Inc. | Glucose-dependent insulinotropic polypeptide receptor antagonists and uses thereof |
| US12471842B2 (en) | 2023-09-12 | 2025-11-18 | Reprieve Cardiovascular, Inc. | Fluid therapy based on adjusted urine output rate, and associated systems, devices, and methods |
| WO2025153045A1 (zh) * | 2024-01-18 | 2025-07-24 | 上海拓界生物医药科技有限公司 | 一种吡啶并噻吩-2-羧酸衍生物及其制备方法和用途 |
| TW202539633A (zh) | 2024-02-01 | 2025-10-16 | 美商輝瑞股份有限公司 | 葡萄糖依賴性促胰島素多肽受體拮抗劑及其用途 |
| WO2025175244A1 (en) | 2024-02-16 | 2025-08-21 | Reprieve Cardiovascular, Inc. | Urine output sensing without use of an indwelling catheter, and associated systems, devices, and methods |
| US20250326741A1 (en) | 2024-04-22 | 2025-10-23 | Pfizer Inc. | Glucose-dependent insulinotropic polypeptide receptor antagonists and uses thereof |
| WO2026013531A1 (en) | 2024-07-10 | 2026-01-15 | Pfizer Inc. | Spiro[2.5]octane compounds |
| WO2026033382A1 (en) | 2024-08-07 | 2026-02-12 | Pfizer Inc. | Heterocyclic glp-1r modulators |
| WO2026042018A1 (en) | 2024-08-21 | 2026-02-26 | Pfizer Inc. | 4-{4-[(1-{[4-(propan-2-yl)phenyl]carbamoyl)-d-prolyl)amino]cyclohexyl}benzoic acid derivatives as gipr antagonists for the treatment of diabetes |
| WO2026078617A1 (en) | 2024-10-11 | 2026-04-16 | Pfizer Inc. | Glucose-dependent insulinotropic polypeptide receptor antagonists and uses thereof |
| WO2026078674A1 (en) | 2024-10-13 | 2026-04-16 | Pfizer Inc. | Heterocyclic derivatives as glucose-dependent insulinotropic polypeptide receptor antagonists and uses thereof |
| WO2026078672A1 (en) | 2024-10-13 | 2026-04-16 | Pfizer Inc. | Glucose-dependent insulinotropic polypeptide receptor antagonists and uses thereof |
| WO2026078671A1 (en) | 2024-10-13 | 2026-04-16 | Pfizer Inc. | Heterocyclic compounds as glucose-dependent insulinotropic polypeptide receptor antagonists |
| WO2026078670A1 (en) | 2024-10-13 | 2026-04-16 | Pfizer Inc. | Heterocyclic derivatives as glucose-dependent insulinotropic polypeptide receptor antagonists |
| WO2026078673A1 (en) | 2024-10-13 | 2026-04-16 | Pfizer Inc. | Glucose-dependent insulinotropic polypeptide receptor antagonists and uses thereof |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| CA1146866A (en) | 1979-07-05 | 1983-05-24 | Yamanouchi Pharmaceutical Co. Ltd. | Process for the production of sustained release pharmaceutical composition of solid medical material |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| DE3438830A1 (de) | 1984-10-23 | 1986-04-30 | Rentschler Arzneimittel | Nifedipin enthaltende darreichungsform und verfahren zu ihrer herstellung |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| KR0182801B1 (ko) | 1991-04-16 | 1999-05-01 | 아만 히데아키 | 고체 분산체의 제조방법 |
| US5340591A (en) | 1992-01-24 | 1994-08-23 | Fujisawa Pharmaceutical Co., Ltd. | Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine |
| JP3265680B2 (ja) | 1992-03-12 | 2002-03-11 | 大正製薬株式会社 | 経口製剤用組成物 |
| US5612359A (en) | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
| DE19504832A1 (de) | 1995-02-14 | 1996-08-22 | Basf Ag | Feste Wirkstoff-Zubereitungen |
| TW536540B (en) | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
| ATE364374T1 (de) | 1997-08-11 | 2007-07-15 | Pfizer Prod Inc | Feste pharmazeutische dispersionen mit erhöhter bioverfügbarkeit |
| WO2000001389A1 (en) | 1998-07-06 | 2000-01-13 | Bristol-Myers Squibb Co. | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists |
| GB0012362D0 (en) * | 2000-05-22 | 2000-07-12 | Aventis Pharma Ltd | Chemical compounds |
| DZ3347A1 (fr) * | 2000-05-22 | 2001-11-29 | Aventis Pharma Inc | Dérivés d'arylméthylamine pour leur utilisation comme inhibiteurs de la tryptase |
| GB0021831D0 (en) * | 2000-09-06 | 2000-10-18 | Astrazeneca Ab | Chemical compounds |
| KR100869616B1 (ko) | 2004-05-12 | 2008-11-21 | 화이자 프로덕츠 인코포레이티드 | 프롤린 유도체 및 그의 다이펩티딜 펩티다제－ｉｖ저해제로서의 용도 |
| JP5190448B2 (ja) | 2006-04-20 | 2013-04-24 | ファイザー・プロダクツ・インク | グルコキナーゼ仲介疾患を予防および治療するための縮合フェニルアミド複素環化合物 |
| CA2659060A1 (en) * | 2006-06-30 | 2008-01-10 | Sepracor Inc. | Fused heterocyclic inhibitors of d-amino acid oxidase |
| US20090036425A1 (en) | 2007-08-02 | 2009-02-05 | Pfizer Inc | Substituted bicyclolactam compounds |
| EP2318370A1 (en) | 2008-07-29 | 2011-05-11 | Pfizer Inc. | Fluorinated heteroaryls |
| MY155418A (en) | 2008-08-28 | 2015-10-15 | Pfizer | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives |
| WO2010086820A1 (en) | 2009-02-02 | 2010-08-05 | Pfizer Inc. | 4-amino-5-oxo-7, 8-dihydropyrimido [5,4-f] [1,4] oxazepin-6 (5h) -yl) phenyl derivatives, pharmaceutical compositions and uses thereof |
| US20110319379A1 (en) | 2009-03-11 | 2011-12-29 | Corbett Jeffrey W | Substituted Indazole Amides And Their Use As Glucokinase Activators |
| MY151246A (en) | 2009-03-11 | 2014-04-30 | Pfizer | Benzofuranyl derivatives |
| WO2010106457A2 (en) | 2009-03-20 | 2010-09-23 | Pfizer Inc. | 3-oxa-7-azabicyclo[3.3.1]nonanes |
| CA2759843A1 (en) | 2009-05-08 | 2010-11-10 | Pfizer Inc. | Gpr 119 modulators |
| WO2010128414A1 (en) | 2009-05-08 | 2010-11-11 | Pfizer Inc. | Gpr 119 modulators |
| NZ596467A (en) | 2009-06-05 | 2014-01-31 | Pfizer | L- ( piperidin-4-yl) -pyrazole derivatives as gpr 119 modulators |
| WO2011005611A1 (en) | 2009-07-09 | 2011-01-13 | Merck Sharp & Dohme Corp. | Neuromedin u receptor agonists and uses thereof |
| EP2954780A1 (en) | 2009-07-24 | 2015-12-16 | Baylor College Of Medicine | Methods of modulation of branched chain acids and uses thereof |
| US20120022116A1 (en) | 2010-07-20 | 2012-01-26 | Huayun Deng | Compositions and methods for the treatment of pathological condition(s) related to gpr35 and/or gpr35-herg complex |
| EP3555064B9 (en) | 2016-12-16 | 2023-03-01 | Pfizer Inc. | Glp-1 receptor agonists and uses thereof |
| PE20191817A1 (es) | 2017-05-11 | 2019-12-27 | Bristol Myers Squibb Co | Tienopiridinas y benzotiofenos utiles como inhibidores de cinasa 4 asociada al receptor de interleucina 1 (irak4) |
| TW202115086A (zh) * | 2019-06-28 | 2021-04-16 | 美商輝瑞大藥廠 | Bckdk抑制劑 |
-
2020
- 2020-06-24 TW TW109121446A patent/TW202115086A/zh unknown
- 2020-06-26 US US16/912,828 patent/US11542270B2/en active Active
- 2020-06-26 PY PY202002030111A patent/PY2030111A/es unknown
- 2020-06-26 EP EP20736441.5A patent/EP3990461A1/en active Pending
- 2020-06-26 JP JP2021576778A patent/JP2022540000A/ja active Pending
- 2020-06-26 WO PCT/IB2020/056066 patent/WO2020261205A1/en not_active Ceased
- 2020-06-26 UY UY0001038768A patent/UY38768A/es not_active Application Discontinuation
- 2020-06-26 CA CA3144869A patent/CA3144869C/en active Active
- 2020-10-23 US US17/078,257 patent/US11059833B2/en active Active